Erratum to: Immunomodulation after ischemic stroke: potential mechanisms and implications for therapy
- PMID: 29047358
- PMCID: PMC5646155
- DOI: 10.1186/s13054-017-1834-7
Erratum to: Immunomodulation after ischemic stroke: potential mechanisms and implications for therapy
Erratum for
-
Immunomodulation after ischemic stroke: potential mechanisms and implications for therapy.Crit Care. 2016 Dec 7;20(1):391. doi: 10.1186/s13054-016-1573-1. Crit Care. 2016. PMID: 27923376 Free PMC article. Review.
Similar articles
-
Immunomodulation after ischemic stroke: potential mechanisms and implications for therapy.Crit Care. 2016 Dec 7;20(1):391. doi: 10.1186/s13054-016-1573-1. Crit Care. 2016. PMID: 27923376 Free PMC article. Review.
-
The use of ADSCs as a treatment for chronic stroke.Cell Transplant. 2014;23(4-5):541-7. doi: 10.3727/096368914X678409. Cell Transplant. 2014. PMID: 24816449 Review.
-
Immunity and stroke, the hurdles of stroke research translation.Int J Stroke. 2017 Feb;12(2):123-131. doi: 10.1177/1747493016676622. Epub 2016 Oct 26. Int J Stroke. 2017. PMID: 27784822 Review.
-
Endothelial progenitor cells in ischemic stroke: an exploration from hypothesis to therapy.J Hematol Oncol. 2015 Apr 11;8:33. doi: 10.1186/s13045-015-0130-8. J Hematol Oncol. 2015. PMID: 25888494 Free PMC article. Review.
-
Activation of RXR/PPARγ underlies neuroprotection by bexarotene in ischemic stroke.Pharmacol Res. 2015 Dec;102:298-307. doi: 10.1016/j.phrs.2015.10.009. Epub 2015 Nov 4. Pharmacol Res. 2015. PMID: 26546745
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
